| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 02/25/2010 | WO2010022380A2 Linear polyol stabilized polyfluoroacrylate compositions |
| 02/25/2010 | WO2010022320A2 Polymeric benzyl carbonate-derivatives |
| 02/25/2010 | WO2010022017A2 Method and composition for enhancing hematopoietic stem cell mobilization |
| 02/25/2010 | WO2010020602A1 Dabigatran for percutaneous interventional cardiac catheterisation |
| 02/25/2010 | WO2010020423A2 Methods for treating bleeding disorders |
| 02/25/2010 | WO2010020198A1 A composition for making pathological tissues dehydration and/or contraction |
| 02/25/2010 | WO2009149795A3 Heterocyclic cyclopropyl-substituted fxr binding compounds |
| 02/25/2010 | WO2009133455A3 Pharmaceutical composition of clodipogrel |
| 02/25/2010 | US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c |
| 02/25/2010 | US20100048654 Use of valsartan or its metabolite to in hibit platelet aggregation |
| 02/25/2010 | US20100048611 Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof |
| 02/25/2010 | US20100048548 Imino-oxazolidines and use thereof |
| 02/25/2010 | US20100048488 Immunomodulatory peptides |
| 02/25/2010 | US20100048477 Method for prevention of platelet aggregation employing an rgd-enriched gelatine-like proteins |
| 02/25/2010 | US20100048473 Modified Protein Polymers |
| 02/25/2010 | US20100047367 Compounds and methods for their use |
| 02/25/2010 | US20100047352 Compositions and methods for treating excessive bleeding |
| 02/25/2010 | US20100047335 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
| 02/25/2010 | US20100047313 Medical devices having a coating for electromagnetically-controlled release of therapeutic agents |
| 02/25/2010 | CA2735058A1 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
| 02/25/2010 | CA2734794A1 Dabigatran for percutaneous interventional cardiac catheterisation |
| 02/25/2010 | CA2731304A1 Methods for treating bleeding disorders |
| 02/25/2010 | CA2731184A1 Polymeric benzyl carbonate-derivatives |
| 02/24/2010 | EP2157178A1 Antibody against von Willebrand Factor cleaving enzyme and assay system using the same |
| 02/24/2010 | EP2157089A1 The therapeutic uses of imidazol-5-carboxylic acid derivatives |
| 02/24/2010 | EP2157084A1 5-phenyl-3-pyridazinone derivative |
| 02/24/2010 | EP2155756A1 Processes for the preparation of clopidogrel |
| 02/24/2010 | EP2155746A2 Diazaquinolones that inhibit prolyl hydroxylase activity |
| 02/24/2010 | EP2155723A2 New solid forms of fxa inhibitors |
| 02/24/2010 | EP2155184A2 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 02/24/2010 | EP1397167B1 Wound closure system and methods |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/23/2010 | USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | US7667052 Bioactive substance |
| 02/23/2010 | US7667027 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β) |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12 |
| 02/23/2010 | US7666874 hypereosinophilic syndrome with resistance to imatinib |
| 02/23/2010 | US7666857 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| 02/23/2010 | US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics |
| 02/23/2010 | US7666830 Nutritional composition preventing bacterial overgrowth |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | US7666401 Compositions comprising a ligand of Chemerin R |
| 02/23/2010 | CA2378945C Multi-dose erythropoietin formulations |
| 02/18/2010 | WO2010019847A2 Aptamer inhibition of thrombus formation |
| 02/18/2010 | WO2010019261A1 Use of gdf traps to increase red blood cell levels |
| 02/18/2010 | WO2010018847A1 Recombinant protein-s composition |
| 02/18/2010 | WO2010018837A2 Protein cross-linking inhibitor |
| 02/18/2010 | WO2010018836A2 Polyglutamine aggregation inhibitor |
| 02/18/2010 | WO2010018278A2 Composition comprising crystallisation inhibitory substances |
| 02/18/2010 | WO2010017598A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041744 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 02/18/2010 | US20100041716 Nitroxides for use in treating or preventing hypercholesterolemia |
| 02/18/2010 | US20100041668 Compositions and methods for treating thrombocytopenia |
| 02/18/2010 | US20100041646 Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants |
| 02/18/2010 | US20100041636 Novel kinase inhibitors |
| 02/18/2010 | US20100040617 Method of Using CD100 (or Sema4D) to Mediate Platelet Activation and Inflammatory Responses |
| 02/18/2010 | US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 02/18/2010 | US20100040596 Use of matrix metalloproteinase-10 (mmp-10) for thrombolytic treatments |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | CA2733911A1 Use of gdf traps to increase red blood cell levels |
| 02/18/2010 | CA2733642A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | CA2732881A1 Composition that comprises crystallisation inhibitory substances |
| 02/18/2010 | CA2732809A1 Aptamer inhibition of thrombus formation |
| 02/17/2010 | EP2152689A1 Analogues of cilostazol |
| 02/17/2010 | EP2152237A1 Novel pharmaceutical composition |
| 02/17/2010 | EP2152233A1 High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant |
| 02/17/2010 | EP2152085A1 Erythropoietin complementation or replacement |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | CN100590124C Tricyclic androgen receptor modulator compounds and method |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662843 Isoxazoline compounds having MIF antagonist activity |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662804 Selective, tissue-specific TPO receptor agonists; thrombocytopenia resulting from radiation or chemotherapy; drug screening; [(N-substituted-2-oxo-1,2-dihydroindol-3-ylidene)hydrazino]-2-phenols; amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injuries, muscular dystrophy |
| 02/16/2010 | US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/16/2010 | US7662548 Method of screening for modulators of HIV infection |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | CA2452918C New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2154231C Process for the preparation of a c1-esterase inhibitor concentrate (c1-inh) and concentrate thus obtained, for therapeutic uses |
| 02/11/2010 | WO2010017122A2 Methods of treating thalassemia |
| 02/11/2010 | WO2010017070A1 Anti-hepcidin-25 selective antibodies and uses thereof |
| 02/11/2010 | WO2010015668A1 Conjugated proteins with prolonged in vivo efficacy |
| 02/11/2010 | WO2010015144A1 The hydrosulfate of prasugrel, its pharmaceutical combination and uses thereof |
| 02/11/2010 | WO2009130602A3 Factor ix conjugates with extended half-lives |
| 02/11/2010 | US20100035955 Stabilised Composition Comprising ACE Inhibitors |
| 02/11/2010 | US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors |
| 02/11/2010 | US20100035930 UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa |
| 02/11/2010 | US20100035888 Diaryl Urea for Treating Pulmonary Hypertension |
| 02/11/2010 | US20100035857 N-[3-(4-{(2S,3R)-2-(-(4-{[(2S, 5S, 3R, 4R, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)perhydro-2H-pyran-2-yl]ethyl-2-yl}phenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phenyl)propyl]-N-methylmethanesulfonamide; anticholesterol agent; low density lipoprotein; treating atherosclerosis |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |